Helps 68% of Patients: Experimental Coronavirus Medication Tested in the US
According to new data based on patient observations, more than two-thirds of seriously ill patients with COVID-19 improved after treatment with Remdesivir, an experimental drug developed by California-based Gilead Sciences Inc. Writes about it New York Post.
Analysis published New England Medical Journaldoes not detail what other treatments the 61 hospitalized patients received, and data for eight of them were not included - in one case due to dosing error.
The author of the article called the results “encouraging,” but warned that it was difficult to interpret the results because they did not include comparison with the control group, as would be the case in a randomized clinical trial. In addition, the number of patients was small, the details disclosed were limited, and the observation time was relatively short.
The study included patients in the United States, Europe, Canada, and Japan who received a 10-day course of intravenous Remdesivir.
Before treatment, 30 patients were on a ventilator, and four were connected to a machine that passes the patient's blood through an artificial oxygenator.
After completing the course of treatment with Remdesivir and observation for 18 days, 36 patients, or 68%, showed a significant improvement. More than half of the 30 patients who were on ventilators at the start of the study were able to breathe on their own. 25 patients, or 47%, were discharged from the hospital. Seven patients, 13% of the total number studied, died.
Twelve patients, 23%, had serious side effects, including multiple organ dysfunction syndrome, septic shock, and acute kidney damage.
“We look forward to seeing the results of controlled clinical trials to confirm our findings,” wrote Dr. Jonathan Grain, lead article author and director of epidemiology at Cedars-Sinai Medical Center in Los Angeles.
There are currently no approved treatments or prophylactic vaccines against COVID-19, a respiratory disease caused by the new coronavirus, which has killed more than 117 people worldwide.
Gilead sharply curtailed its Remdesivir program in March and is conducting its own clinical trials of the antiviral drug, with results expected in the coming weeks. Researchers in China and the US National Institutes of Health are also testing Remdesivir on COVID-19 patients.
stdClass Object ([term_id] => 1 [name] => Miscellaneous [taxonomy] => category [slug] => no_theme)Miscellaneous
stdClass Object ([term_id] => 12 [name] => In the US [taxonomy] => category [slug] => novosti-ssha)In the U.S.
stdClass Object ([term_id] => 1375 [name] => treatment [taxonomy] => post_tag [slug] => lechenie)treatment
stdClass Object ([term_id] => 28340 [name] => coronavirus [taxonomy] => post_tag [slug] => koronavirus)coronavirus
stdClass Object ([term_id] => 28347 [name] => Special projects [taxonomy] => category [slug] => specproekty)Special Projects
stdClass Object ([term_id] => 28353 [name] => READ ABOUT CORONAVIRUS [taxonomy] => special [slug] => kitajskij-koronavirus)
Read also on ForumDaily:
Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. And don't forget to subscribe to ForumDaily Woman and ForumDaily New York - there you will find a lot of interesting and positive information.